Diabetes and diabetic-related eye diseases are quite prevalent in our area of the country. Now, for the first time in medical history, patients with Diabetic Macular Edema (DME) have access to an exciting FDA-approved medicine called Lucentis that is shown to help them rapidly regain substantial amounts of lost vision. Previous treatments for Diabetic Macular Edema stabilized vision, but did not improve patients’ sight. For the first time, we have a treatment that can improve vision.
Our goal at OSM Eye Clinic has always been to offer patients the most advanced, comprehensive eye care available today. We’re proud of our history of introducing new lens implants for cataract patients, breakthroughs in laser technology for nearsighted and farsighted patients and recent advancements in treating astigmatism. Our commitment to leading edge technology and surgical techniques is surpassed only by our dedication to providing professional and personal eye care…right here at home.
However, this recent announcement may be among our most significant in recent history, especially for diabetics. The ability to restore ‘lost vision’ from diabetes-related eye disease is extremely rare. The announcement at Genetech – the manufacturer of Lucentis – is one of the most dramatic breakthroughs in ophthalmic research history and we’re extremely proud to be one of the first local practice practitioners to offer this treatment to our DME diabetic patients.
This approval is an important advancement in the fight against blindness for diabetic patients. With Lucentis now available for our DME patients, therapy can begin immediately in an effort to restore lost vision and make a significant difference in the lives of our patients with DME.
DME is an eye condition that causes blurred vision, severe vision loss and sometimes blindness. Diabetes is now the leading cause of new cases of blindness in working-aged Americans, and DME is estimated to affect more than 560,000 people with diabetes.
Lucentis is only FDA-approved medicine shown to rapidly and significantly improve vision loss from DME and is the first major treatment advancement for the disease in more than 25 years.
By: Saad Ahmad, MD
Retinal Specialist, OSM Eye Clinic